Showing results (181-190 of 435) with videos related to

Sort By:
Pageof 44
Gut|November 1, 2017
Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumabThibault Mazard, Piyaporn Boonsirikamchai, Michael J Overman, et al.
Nature Cancer|July 11, 2024
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistanceChristopher E Whitehead, Elizabeth K Ziemke, Christy L Frankowski-McGregor, et al.
Cancer Research|December 20, 2011
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancerHong Yang, Brian Higgins, Kenneth Kolinsky, et al.
Cancer|March 30, 2011
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?Antoine Brouquet, Michael J Overman, Scott Kopetz, et al.
The Oncologist|December 28, 2022
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I TrialAlexander Spira, Michael S Wertheim, Edward J Kim, et al.
BMC Cancer|December 20, 2019
The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancerXiaotao Zhang, Gladys Browman, Wesley Siu, et al.
Scientific Reports|April 4, 2026
IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancerAkash R Boda, Irfan N Bandey, Saikat Chowdhury, et al.
Scientific Reports|September 11, 2023
Global proteomic identifies multiple cancer-related signaling pathways altered by a gut pathobiont associated with colorectal cancerEwa Pasquereau-Kotula, Giulia Nigro, Florent Dingli, et al.
Annals of Surgery|February 22, 2013
Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapyAndreas Andreou, Thomas A Aloia, Antoine Brouquet, et al.
The Oncologist|September 22, 2020
Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic MalignanciesShehara Mendis, Seerat Anand, Joanna M Karasinska, et al.
Pageof 44